RxDoctor Payments Data

Luis Magdaleno, MD

Family Medicine · Rancho Pulos Verdes, CANPI 1164492013

Payments from drug & device makers

$695in general payments, 2019–2025

Across 25 payments — averaging $27.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Revance Therapeutics, Inc.$224
  • AstraZeneca$174
  • Galderma Laboratories, L.p.$121
  • Novo Nordisk$109
  • Pfizer$21
  • Johnson & Johnson$19
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$695 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$32,971
Medicare patients
157
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$108,016
FarxigaDapagliflozin Propanediol90$78,474
JanuviaSitagliptin Phosphate51$72,574
OzempicSemaglutide48$65,694
JardianceEmpagliflozin42$45,770
TradjentaLinagliptin24$32,456
XareltoRivaroxaban56$23,131
Breo ElliptaFluticasone/Vilanterol45$22,751
JanumetSitagliptin Phos/Metformin Hcl17$17,579
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,153
MyrbetriqMirabegron15$10,653
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$6,495
Rosuvastatin Calcium343$5,988
Atorvastatin Calcium458$4,609
Omeprazole272$3,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$108,016120 claims
AstraZenecaFarxiga$174$78,47490 claims
Novo NordiskOzempic$109$65,69448 claims
Johnson & JohnsonXarelto$19$23,13156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Rancho Pulos Verdes

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →